United Therapeutics Co. (NASDAQ:UTHR) is Polaris Capital Management LLC’s 9th Largest Position

Polaris Capital Management LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,850 shares of the biotechnology company’s stock after selling 10,100 shares during the quarter. United Therapeutics makes up 2.2% of Polaris Capital Management LLC’s investment portfolio, making the stock its 9th largest position. Polaris Capital Management LLC owned 0.30% of United Therapeutics worth $46,522,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Cetera Investment Advisers raised its stake in United Therapeutics by 8.7% in the second quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company’s stock worth $1,964,000 after buying an additional 493 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock valued at $535,000 after purchasing an additional 594 shares during the period. CWM LLC grew its stake in United Therapeutics by 108.3% in the third quarter. CWM LLC now owns 4,006 shares of the biotechnology company’s stock worth $1,436,000 after purchasing an additional 2,083 shares during the period. Ritholtz Wealth Management lifted its position in United Therapeutics by 14.3% during the third quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 105 shares during the period. Finally, CHICAGO TRUST Co NA purchased a new stake in shares of United Therapeutics in the 3rd quarter worth about $204,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.6 %

NASDAQ:UTHR opened at $345.64 on Tuesday. The stock has a market capitalization of $15.43 billion, a PE ratio of 15.18, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The stock’s 50-day moving average price is $362.37 and its 200-day moving average price is $358.13. United Therapeutics Co. has a 52 week low of $210.64 and a 52 week high of $417.82.

Wall Street Analyst Weigh In

Several research analysts have issued reports on UTHR shares. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $382.08.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,864 shares of company stock valued at $41,036,365 in the last three months. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.